| Rituximab therapy for childhood Evans syndrome. | |
| | |
MedLine Citation:
|
PMID: 18055994 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The safety and efficacy of rituximab have been retrospectively assessed in 17 children with Evans syndrome. Patients received 4 or 3 weekly doses of rituximab (375 mg/m(2) per dose) associated with prednisone, alone (14 patients) or associated with other immunosuppressive drugs. Complete or partial remission of at least one cytopenia was achieved in 13 out of the 17 patients (76%), and lasted in 11 of them with a mean follow-up of 2.4 years (range 0.5-7 years). Steroid therapy was stopped or tapered at 50-100% of the baseline dosage in all long-term responders. Moderate side effects and infection occurred only in 4 and 1 children respectively. |
| | |
Authors:
|
Brigitte Bader-Meunier; Nathalie Aladjidi; Françoise Bellmann; Fabrice Monpoux; Brigitte Nelken; Alain Robert; Corinne Armari-Alla; Capucine Picard; Françoise Ledeist; Martine Munzer; Karima Yacouben; Yves Bertrand; Antoine Pariente; Arnaud Chaussé; Yves Perel; Guy Leverger |
Related Documents
:
|
6893624 - Effect of corticosteroids and fetomaternal disorders on the l:s ratio. 23657264 - Prognostic value of perioperative n-terminal pro-b-type natriuretic peptide in noncardi... 9412914 - Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. 23246374 - Lumbar spinal stenosis: which predictive factors of favorable functional results after ... 19138754 - Tiotropium induced bronchodilation and protection from dynamic hyperinflation is indepe... 20483024 - Effects of minimally invasive techniques for evacuation of hematoma in basal ganglia on... |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Haematologica Volume: 92 ISSN: 1592-8721 ISO Abbreviation: Haematologica Publication Date: 2007 Dec |
Date Detail:
|
Created Date: 2007-12-06 Completed Date: 2008-04-01 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0417435 Medline TA: Haematologica Country: Italy |
Other Details:
|
Languages: eng Pagination: 1691-4 Citation Subset: IM |
Affiliation:
|
Assistance Publique-Hôpitaux de Paris, Service d'Hématologie-Oncologie Pédiatrique, Hôpital Robert Debré, Paris, France. brigitte.badermeunier@rdb.ap-hop-paris.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Anemia, Hemolytic, Autoimmune / complications, drug therapy*, mortality Antibodies, Monoclonal / administration & dosage*, adverse effects Child Child, Preschool Disease-Free Survival Female Follow-Up Studies France Humans Immunologic Factors / administration & dosage*, adverse effects Infant Infection / chemically induced, mortality Male Prednisolone / administration & dosage, adverse effects Purpura, Thrombocytopenic, Idiopathic / complications, drug therapy*, mortality Registries Remission Induction Survival Rate Syndrome |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Immunologic Factors; 0/rituximab; 50-24-8/Prednisolone |
| Comments/Corrections | |
Comment In:
|
Haematologica. 2007 Dec;92(12):1589-96
[PMID:
18055980
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Antithymocyte globulin and cyclosporine for treatment of 44 children with hepatitis associated aplas...
Next Document: Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adul...